• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
Chen Yuanyuan, Li Xiangyu, XU Pengfei, LU Xiaokun, WANG Youmei, XU Peng, DI Bin. Research advances of fentanyl and fentanyl-related substances[J]. Journal of China Pharmaceutical University, 2020, 51(6): 724-730. DOI: 10.11665/j.issn.1000-5048.20200612
Citation: Chen Yuanyuan, Li Xiangyu, XU Pengfei, LU Xiaokun, WANG Youmei, XU Peng, DI Bin. Research advances of fentanyl and fentanyl-related substances[J]. Journal of China Pharmaceutical University, 2020, 51(6): 724-730. DOI: 10.11665/j.issn.1000-5048.20200612

Research advances of fentanyl and fentanyl-related substances

Funds: This study was supported by the National Key Research and Development Program of China for the 13th Five-Year Plan (No.2017YFC0803605,No.2018YFC0807402)
More Information
  • Received Date: October 12, 2019
  • Revised Date: October 12, 2020
  • Fentanyl and fentanyl-related substances are a series of synthetic and powerful anesthetics represented by fentanyl. In recent years,the abuse and trafficking of these substances in many countries around the world are serious which poses a great threat to people"s health and social stability. This paper focuses on the abuse,pharmacological and toxicological action,detection methods and control of fentanyl and fentanyl-related substances and aims to enhance people"s understanding of their basic properties,current research and control so as to provide references for future research.
  • [1]
    . J Beijing Police College(北京警察学院学报),2019(3):109?115.
    [2]
    Yang LH. Reflection on the management of the whole class of fentanyl substances in China[J]. J Yunnan Police Officer Academy(云南警官学院学报),2019(4):1?4.
    [3]
    Liu ZM. Abuse and control of fentanyl and its derivatives:hazards and challenges[J]. Chin J Drug Depend(中国药物依赖性杂志),2017,26(4):274?276.
    [4]
    UNODC. Fentanyl and its anolognes-50 year on[J]. Global SMART Update,2017,17:3?8.
    [5]
    Karila L,Marillier M,Chaumette B,et al. New synthetic opioids:part of a new addiction landscape[J]. Neurosci Biobehav Rev,2019,106:133?140.
    [6]
    Baumann MH,Pasternak GW. Novel synthetic opioids and overdose deaths:tip of the iceberg[J]? Neuropsychopharmacology,2018,43(1):216?217.
    [7]
    UNODC. Understanding the global opioid crisis[J]. Global SMART Update,2019,21:6?9.
    [8]
    Burns SM,Cunningham CW,Mercer SL. DARK classics in chemical neuroscience:fentanyl[J]. ACS Chem Neurosci,2018,9(10):2428?2437.
    [9]
    Comer SD,Cahill CM. Fentanyl:receptor pharmacology,abuse potential,and implications for treatment[J]. Neurosci Biobehav Rev,2019,106:49?57.
    [10]
    Xiao JZ. Pharmacology and clinical practice of remifentanil[J]. J Med Theor Pract (医学理论与实践),2009,22(2):158?160.
    [11]
    Yang S,Xu Q. Research progress in the fentanyl and its derivatives in the treatment of cancer pain[J]. Shanghai Med Pharm J(上海医药),2015(5):32?36.
    [12]
    Pacifici GM. Clinical pharmacology of fentanyl in preterm infants. A review[J]. Pediatr Neonatol,2015,56(3):143?148.
    [13]
    Schaefer CP,Tome ME,Davis TP. The opioid epidemic:a central role for the blood brain barrier in opioid analgesia and abuse[J]. Fluids Barriers CNS,2017,14(1):32.
    [14]
    Ninkovi? J,Roy S. Role of the mu-opioid receptor in opioid modulation of immune function[J]. Amino Acids,2013,45(1):9?24.
    [15]
    Xu L,Li YH. Studies on pharmacological action and clinical application of sufentanil[J]. Anhui Med Pharm J(安徽医药),2011(3):375?377.
    [16]
    Xiao GF,Lv H. Observation on the analgesic effect and stress state of brachial plexus block combined with remifentanil during replantation of severed fingers[J]. J Logist Univ PAPF(武警后勤学院学报),2018,27(6):48?51.
    [17]
    Ma L,Wang XL. Evaluation of sufentanil in intravenous postoperative analgesia and clinical anesthesia[J]. Gen J Stomat(全科口腔医学杂志),2018,5(32):191?192.
    [18]
    Dumas EO,Pollack GM. Opioid tolerance development:a pharmacokinetic/pharmacodynamic perspective[J]. AAPS J,2008,10(4):537?551.
    [19]
    Sutou I,Nakatani T,Hashimoto T,et al. Fentanyl tolerance in the treatment of cancer pain:a case of successful opioid switching from fentanyl to oxycodone at a reduced equivalent dose[J]. J Pain Palliat Care Pharmacother,2015,29(2):161?165.
    [20]
    Neunhoeffer F,Hanser A,Esslinger M,et al. Ketamine infusion as a counter measure for opioid tolerance in mechanically ventilated children:a pilot study[J]. Paediatr Drugs,2017,19(3):259?265.
    [21]
    Volkow ND,Jones EB,Einstein EB,et al. Prevention and treatment of opioid misuse and addiction:a review[J]. JAMA Psychiatry,2019,76(2):208?216.
    [22]
    Hao W,Zhao M,Li J. Addication medicine:theory and practice(成瘾医学:理论和实践)[M]. Beijing:People''''s Medical Publishing House,2016:14?71.
    [23]
    Aceto M. Dependence studies of new compounds in the rhesus monkey,rat and mouse[J]. Problems Drug Dependence ,1996,1998:338.
    [24]
    Pan LS,Cui YY,Ren YH,et al. Dependence -producing potential of remifentanil[J]. Chin J Drug Depend(中国药物依赖性杂志),2002,11(2):107?110.
    [25]
    Bekhit MH. Opioid-induced hyperalgesia and tolerance[J]. Am J Ther,2010,17(5):498?510.
    [26]
    YueK,WenRJ. Neuroimmune mechanism of opiates addiction[J]. J Jianghan Univ(Nat Sci Ed.)[江汉大学学报(自然科学版)],2017,45(3):241?246.
    [27]
    Essawi MY. Fentanyl analogues with a modified propanamido group as potential affinity labels:synthesis and in vivo activity[J]. Pharmazie,1999,54(4):307?308.
    [28]
    Lin H,Higgins P,Loh HH,et al. Bidirectional effects of fentanyl on dendritic spines and AMPA receptors depend upon the internalization of mu opioid receptors[J]. Neuropsychopharmacology,2009,34(9):2097?2111.
    [29]
    Wei X,Wei W. Role of gabapentin in preventing fentanyl-and morphine-withdrawal-induced hyperalgesia in rats[J]. J Anesth,2012,26(2):236?241.
    [30]
    Dolinak D. Opioid toxicity[J]. Acad Forensic Pathol,2017,7(1):19?35.
    [31]
    Liu C,Kang Y. How to evaluate and select sedatives and analgesics considering their cardiovascular and respiratory effects[J]? Chin J Crit Care Intensive Care Med Electron Ed(中华重症医学电子杂志),2017,3(4):291?295.
    [32]
    Liu XB,Xu GP. Research progress of mechanism about remifentanil slowing down heart rate[J]. Med Recap(医学综述),2012,18(23):4027?4029.
    [33]
    Chen L,Zhao YH,Liu XL. Progress in the application of sufentanil in the treatment of cancer pain[J]. Chin J Pain Med(中国疼痛医学杂志),2018,24(11):65?68.
    [34]
    Guo ZF. Clinical application of sufentanil[J]. J Chengde Med Col(承德医学院学报),2016,33(6):516?519.
    [35]
    Qian ZH,Li P,Zheng H,et al. Mass fragmentation characteristics of fentanyl analogue[J]. J Chin Mass Spectrom Soc(质谱学报),2018,39(5):79?88.
    [36]
    Gupta PK,Yadav SK,Bhutia YD,et al. Synthesis and comparative bioefficacy of N-(1-phenethyl-4-piperidinyl)propionanilide (fentanyl) and its 1-substituted analogs in Swiss albino mice[J]. Med Chem Res,2013,22(8):3888?3896.
    [37]
    Swaminathan SK,Fisher J,Kandimalla KK. Sensitive determination of fentanyl in low-volume serum samples by LC-MS/MS[J]. AAPS Pharmscitech,2018,19(7):2812?2817.
    [38]
    Mochizuki A,Nakazawa H,Adachi N,et al. Identification and quantification of mepirapim and acetyl fentanyl in authentic human whole blood and urine samples by GC-MS/MS and LC-MS/MS[J]. Forensic Toxicol,2018,36(1):81?87.
    [39]
    Misailidi N,Athanaselis S,Nikolaou P,et al. A GC-MS method for the determination of furanylfentanyl and ocfentanil in whole blood with full validation[J]. Forensic Toxicol,2019,37(1):238?244.
    [40]
    Liu CM. The application prospect of fourier transform infrared spectroscopy in narcotics control area[J]. Spectrosc Spectral Anal(光谱学与光谱分析),2018,38(S1):400?401.
    [41]
    Mallette JR,Casale JF,Toske SG,et al. Characterization of (2R,4S)- and (2R,4R)-2-Methylfentanyl and their differentiation from cis- and trans-3-methylfentanyl[J]. Forensic Chem,2018,8:64?71.
    [42]
    Li KK,Miao CY,Wang DK. Detection of drugs by raman spectroscopy and data analysis based on R software[J]. J Light Scat (光散射学报),2018,30(2):156?162.
    [43]
    Kong LC,Zuo GM,Liu GQ,et al. Surface-enhanced raman spectroscopy for trace fentanyl detection in water[J]. J Light Scat (光散射学报),2010,22(1):34?38.
    [44]
    Tiscione NB,Wegner K. Validation of the Neogen?Fentanyl ELISA kit for blood and urine[J]. J Anal Toxicol,2017,41(4):313?317.
    [45]
    Smith JS,Mochel JP,Borts DJ,et al. Adverse reactions to fentanyl transdermal patches in calves:a preliminary clinical and pharmacokinetic study[J]. Vet Anaesth Analg,2018,45(4):575?580.
    [46]
    Wan HN. Application and development of immunoassay in drug testing and identification[J]. J Liaoning Police Coll(辽宁警察学院学报),2018,20(2):65?69.
    [47]
    Center For Medical Device Evaluation. NMPA. Notice of issuance of registered designated inspection notice on 30 August,2019[EB/OL].(2019-08-30)[2019-09-12].https://www.cmde.org.cn/CL0151/19680.html.
    [48]
    Zaknoun H,Binette MJ,Tam M. Analyzing fentanyl and fentanyl analogues by ion mob spectrometry[J]. Int J Ion Mobil Spectrom,2019,22(1):1?10.
    [49]
    UNODC. Recommended methods for the identification and analysis of fentanyl and its analogues in biological specimens:manual for use by national drug analysis laboratories[EB/OL]. (2017-12-07)[2019-11-11].www.unodc.org/documents/scientific/Recommended_methods_for_the_identification_and_analysis_of_fentanyl.pdf.
    [50]
    Zhang WY,Lin JF,Yan J,et al. Rapid screening of fentanyl substances and their precursors without the standards[J]. J Anal Sci(分析科学学报),2019,35(5):635?642.
    [51]
    United States Drug Enforcement Administration. Schedules of controlled substances:temporary placement of fentanyl-related substances in schedule I[EB/OL]. (2018-02-06)[2019-11-11]. https://www.deadiversion.usdoj.gov/fed_regs/rules/2018/fr0206_4.htm.
    [52]
    EMCDDA. Fentanils and synthetic cannabinoids:driving greater complexity into the drug situation-An update from the EU Early Warning System[EB/OL]. (2018-06-01)[2019-11-11]. http://www.emcdda.europa.eu/publications/rapid-communications/fentanils-and-synthetic-cannabinoids-ews-update_en.
    [53]
    Supreme people''''s court. Notice on the issuance of the catalogue of varieties of narcotic drugs and the catalogue of psychotropic drugs[EB/OL]. (2019-11-11)[2019-11-11]. http://www.qlgl.gov.cn/show-20-5239-1.html.
    [54]
    China National Narcotic Control Commision. China conducts the management of four fentanyl substances such as carfentanil[EB/OL]. (2017-02-16)[2019-11-11]. http://www.nncc626.com/2017-02/16/c_129482280_5.htm.
  • Related Articles

    [1]CHEN Xin, YANG Qian, YOU Qidong, GUO Xiaoke. Advances of inhibitors targeting MLL1-WDR5 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2022, 53(2): 125-136. DOI: 10.11665/j.issn.1000-5048.20220201
    [2]ZHANG Yuxin, DING Ming, LIU Jun. Research progress of proximity labeling technology based on biotin ligase in proteomics[J]. Journal of China Pharmaceutical University, 2022, 53(1): 18-24. DOI: 10.11665/j.issn.1000-5048.20220103
    [3]MO Xiaofei, XU Xiaoli, WANG Yalou, YOU Qidong. Advances in the HIF-1α/p300 protein-protein interaction inhibitors[J]. Journal of China Pharmaceutical University, 2017, 48(5): 515-522. DOI: 10.11665/j.issn.1000-5048.20170502
    [4]LIU Fang, SUN Haopeng, YOU Qidong. Advances in small-molecule inhibitors targeting Hsp90-Cdc37 protein-protein interaction[J]. Journal of China Pharmaceutical University, 2015, 46(3): 272-278. DOI: 10.11665/j.issn.1000-5048.20150303
    [5]The Effect of Inducer on Enzyme Activity of Dihydropyri midinase[J]. Journal of China Pharmaceutical University, 1999, (3): 60-63.
    [6]Purification and Characterization of Potent Fibrinolytic Enzyme from Earthworm[J]. Journal of China Pharmaceutical University, 1997, (6): 48-51.
    [7]Pharmacokinetic Studies of Nevin Fibrinolytic Enzyme[J]. Journal of China Pharmaceutical University, 1997, (2): 107-110.
    [8]Effect of Astragalus on Fluidity of Lipid Regions and Conformation of Protein of Human Erythrocyte Membranes[J]. Journal of China Pharmaceutical University, 1994, (4): 49-52.
    [9]Interaction of Four Berbamine Derivatives with Erythrocyte Membrane Ca~(2 )-Mg~(2 )-ATPase[J]. Journal of China Pharmaceutical University, 1993, (5): 304-307.
    [10]Wu Wutong. Advances in enzyme drugs[J]. Journal of China Pharmaceutical University, 1982, (3): 59-64.
  • Cited by

    Periodical cited type(3)

    1. 李锦华,祁萍,乔慧. ALK-TKI耐药后获得性RET融合晚期非小细胞肺癌1例报道并文献复习. 肿瘤防治研究. 2024(08): 703-706 .
    2. 王瑞峰,赵相欣,孙印,秦桥花,赵冬梅. 降解FAK的PROTAC分子的设计合成及生物活性研究. 中国药物化学杂志. 2023(07): 481-489 .
    3. 王梓灵,郭瑜婕,朱芸芸,陈乐,吴婷,刘大会,黄必胜,杜鸿志. 金花茶有效部位抑制表皮生长因子受体(EGFR)抗非小细胞肺癌的作用机制研究. 中国中药杂志. 2021(20): 5362-5371 .

    Other cited types(2)

Catalog

    Article views PDF downloads Cited by(5)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return